Lucius Cary
Founder and Managing Director @ Oxford Technology Management
Oxford, United Kingdom
Lucius Cary is a seed investor at Oxford Technology Management in Oxford focused on Medical and Biopharma. Lucius Cary is the founder and managing director of Oxford Technology. He has a degree in engineering and economics from Oxford University, an MBA from Harvard Business School and was an engineering apprentice at the Atomic Energy Research Establishment, Harwell.After forming and raising finance for his first business in 1972, he founded"Venture Capital Report" in 1978 and was its managing director for 17 years. In March 1996, he became chairman and reduced his day-to-day involvement in order to concentrate more fully on Oxford Technology Management's investment activities. Oxford Technology Management raised its first fund to invest in start-up and early-stage technology companies in 1983. In 2003, he was awarded an OBE for services to business.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Lucius Cary invests in
Stages Lucius Cary invests in
Countries Lucius Cary invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (50%)
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Seed 1 (50%)
- Angel 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ducentis BioTherapeutics
|
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection andautoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage. | $1.1M / Angel / Aug 01, 2017 | |
|
Ducentis BioTherapeutics
|
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Our target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection andautoimmune and inflammatory disease affecting the lung, liver, kidney, eye, bone and cartilage. | $105K / Seed / Dec 14, 2015 |
Co-Investors
Oxford Technology Management was founded by Lucius Cary, and since 1983 has specialised in making and managing investments in start-up and early stage technology-based businesses with high growth prospects.The OTM team are all scientists or engineers by background, and understanding the technology is the starting point for any investment thatthey may make.The Investment policy of Oxford Technology Management is to construct a portfolio of investments with the following characteristics:unlisted, UK based, technology businesses investments typically in the range of £100,000 - £2,000,000, although it can then invest similar amounts in subsequent rounds in most cases located within easy reach of Oxford to allow a more 'hands on' management strategy It is expected that approximately half of the funds will be invested in early stage companies (those which have achieved some initial sales) and the balance in start-up companies which are at an earlier stage.
Oxford Technology Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrea Mica
Director
|
|||
David Livesley
Non-Executive Chairman
|
|||
|
Lucius Cary
Founder and Managing Director
|
|||
Michael Penington
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Lucius Cary invest in?
Lucius Cary invests primarily in Medical, Biopharma and Health Care startups, most often at Seed and Angel stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lucius Cary?
Public channels for Lucius Cary include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Lucius Cary last invest?
The most recent investment recorded for Lucius Cary closed in Aug 2017. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
